Follow
Patrick T. Gunning
Patrick T. Gunning
Canada Research Chair and Associate Professor of Chemistry
Verified email at utoronto.ca
Title
Cited by
Cited by
Year
Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts
X Zhang, P Yue, BDG Page, T Li, W Zhao, AT Namanja, D Paladino, ...
Proceedings of the National Academy of Sciences 109 (24), 9623-9628, 2012
3262012
An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects
KAZ Siddiquee, PT Gunning, M Glenn, WP Katt, S Zhang, C Schroeck, ...
ACS chemical biology 2 (12), 787-798, 2007
2172007
A novel small-molecule disrupts Stat3 SH2 domain–phosphotyrosine interactions and Stat3-dependent tumor processes
X Zhang, P Yue, S Fletcher, W Zhao, PT Gunning, J Turkson
Biochemical pharmacology 79 (10), 1398-1409, 2010
2112010
Recent advances in biosensory and medicinal therapeutic applications of zinc (II) and copper (II) coordination complexes
JA Drewry, PT Gunning
Coordination Chemistry Reviews 255 (3-4), 459-472, 2011
1432011
Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer
B Wingelhofer, HA Neubauer, P Valent, X Han, SN Constantinescu, ...
Leukemia 32 (8), 1713-1726, 2018
1362018
Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein
S Fletcher, J Turkson, PT Gunning
ChemMedChem: Chemistry Enabling Drug Discovery 3 (8), 1159-1168, 2008
1322008
Signal transducer and activator of transcription 3 inhibitors: a patent review
BDG Page, DP Ball, PT Gunning
Expert opinion on therapeutic patents 21 (1), 65-83, 2011
1252011
Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein
S Fletcher, JA Drewry, VM Shahani, BDG Page, PT Gunning
Biochemistry and Cell Biology 87 (6), 825-833, 2009
1252009
Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia
AM Eiring, BDG Page, IL Kraft, CC Mason, NA Vellore, D Resetca, ...
Leukemia 29 (3), 586-597, 2015
1222015
STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor PromotionNK Cells as Tumor Promoters
D Gotthardt, EM Putz, E Grundschober, M Prchal-Murphy, E Straka, ...
Cancer Discovery 6 (4), 414-429, 2016
1172016
Disruption of Transcriptionally Active Stat3 Dimers with Non‐phosphorylated, Salicylic Acid‐Based Small Molecules: Potent in vitro and Tumor Cell Activities
S Fletcher, J Singh, X Zhang, P Yue, BDG Page, S Sharmeen, ...
Chembiochem 10 (12), 1959-1964, 2009
1152009
Progress towards the development of SH2 domain inhibitors
D Kraskouskaya, E Duodu, CC Arpin, PT Gunning
Chemical Society reviews 42 (8), 3337-3370, 2013
1102013
Potent targeting of the STAT3 protein in brain cancer stem cells: a promising route for treating glioblastoma
S Haftchenary, HA Luchman, AO Jouk, AJ Veloso, BDG Page, XR Cheng, ...
ACS medicinal chemistry letters 4 (11), 1102-1107, 2013
1082013
Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity
BDG Page, H Khoury, RC Laister, S Fletcher, M Vellozo, A Manzoli, P Yue, ...
Journal of medicinal chemistry 55 (3), 1047-1055, 2012
1072012
Pharmacologic inhibition of STAT5 in acute myeloid leukemia
B Wingelhofer, B Maurer, EC Heyes, AA Cumaraswamy, A Berger-Becvar, ...
Leukemia 32 (5), 1135-1146, 2018
982018
Advances in covalent kinase inhibitors
A Abdeldayem, YS Raouf, SN Constantinescu, R Moriggl, PT Gunning
Chemical Society Reviews 49 (9), 2617-2687, 2020
952020
Signal transducer and activator of transcription 3 and 5 regulate system Xc-and redox balance in human breast cancer cells
K Linher-Melville, S Haftchenary, P Gunning, G Singh
Molecular and cellular biochemistry 405 (1), 205-221, 2015
822015
Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: structural recognition of STAT SH2 domains
PT Gunning, WP Katt, M Glenn, K Siddique, JS Kim, R Jove, SM Sebti, ...
Bioorganic & medicinal chemistry letters 17 (7), 1875-1878, 2007
822007
Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report
S Haftchenary, M Avadisian, PT Gunning
Anti-cancer drugs 22 (2), 115-127, 2011
782011
Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain
BDG Page, S Fletcher, P Yue, Z Li, X Zhang, S Sharmeen, A Datti, ...
Bioorganic & medicinal chemistry letters 21 (18), 5605-5609, 2011
682011
The system can't perform the operation now. Try again later.
Articles 1–20